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Abstract
Antibody 10E8 targets the membrane-proximal external region (MPER) of HIV-1 gp41, neu-
tralizes >97% of HIV-1 isolates, and lacks the auto-reactivity often associated with MPER-
directed antibodies. The developmental pathway of 10E8 might therefore serve as a promis-
ing template for vaccine design, but samples from time-of-infection—often used to infer the
B cell record—are unavailable. In this study, we used crystallography, next-generation
sequencing (NGS), and functional assessments to infer the 10E8 developmental pathway
from a single time point. Mutational analysis indicated somatic hypermutation of the 2nd-
heavy chain-complementarity determining region (CDR H2) to be critical for neutralization,
and structures of 10E8 variants with V-gene regions reverted to genomic origin for heavy-
and-light chains or heavy chain-only showed structural differences >2 Å relative to mature
10E8 in the CDR H2 and H3. To understand these developmental changes, we used bioin-
formatic sieving, maximum likelihood, and parsimony analyses of immunoglobulin tran-
scripts to identify 10E8-lineage members, to infer the 10E8-unmutated common ancestor
(UCA), and to calculate 10E8-developmental intermediates. We were assisted in this analy-
sis by the preservation of a critical D-gene segment, which was unmutated in most 10E8-
lineage sequences. UCA and early intermediates weakly bound a 26-residue-MPER pep-
tide, whereas HIV-1 neutralization and epitope recognition in liposomes were only observed
with late intermediates. Antibody 10E8 thus develops from a UCA with weak MPER affinity
and substantial differences in CDR H2 and H3 from the mature 10E8; only after extensive
somatic hypermutation do 10E8-lineage members gain recognition in the context of mem-
brane and HIV-1 neutralization.
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Introduction
Although antibodies against the human immunodeficiency virus type 1 (HIV-1) are slow to
appear, after years of chronic infection, roughly half of HIV-1-infected donors develop anti-
bodies capable of neutralizing half of circulating HIV-1 strains [1,2]. These antibodies provide
potential templates to guide HIV-1 vaccine strategies [3,4], and details of their generation and
maturation have generated intense interest. One means to delineate the developmental path-
way of a particular antibody involves a) longitudinal sampling of donors from time of infection,
b) next-generation sequencing of B cell transcripts, and c) identification of members of the
antibody lineage in the longitudinal samples. Thus far, this has been accomplished for three
antibody lineages: the CD4-binding-site-directed CH103 lineage from donor CH505 [5], a sec-
ond CD4-binding site-directed lineage, CH235, from the same donor [6] and the V1V2-dir-
ected VRC26 lineage from donor CAP256 [7]. While details of the developmental pathway for
each of these lineages have proven a boon to the HIV-vaccine field, few broadly neutralizing
antibodies have been identified from longitudinal samples; most broadly neutralizing antibod-
ies have been identified from cross-sectional samples, in which only a few (often one) time
points are available. One such antibody, the 10E8 antibody from donor N152, is perhaps the
broadest of all HIV-1 antibodies thus far identified [8].
The 10E8 antibody recognizes an epitope in the membrane-proximal external region
(MPER) of the HIV-1 gp41 transmembrane glycoprotein. 10E8 belongs to a category of
broadly neutralizing antibodies that includes antibodies 2F5 [9–11], 4E10 [12], and m66.6
[9,11,13,14]. Like other MPER-directed antibodies, the 10E8 antibody is able to recognize its
gp41 epitope in the membrane context [10,15–17], a trait that it appears to acquire during mat-
uration, as this trait is not present in V gene-reverted germline versions of these antibodies.
Both membrane-context recognition and developmental uncertainty have generated consider-
able speculation about the origin of MPER-directed antibodies. Were they generated in
response to other non-HIV-1 antigens [18]? Were the initial B cell recombinants polyreactive
[19]? Or did the membrane-reactivity arise through somatic hypermutation (SHM) in the
periphery, where autoreactivity checkpoints are less stringent [20]?
To address these questions, we attempted to delineate the developmental pathway of the
10E8 antibody. Unfortunately, PBMCs from donor N152, the source of antibody 10E8, were
only sampled at two time points: January and June 2011, both more than 10 years after HIV-1
infection of donor N152; this sparseness of sampling complicated the identification of early
lineage members. We previously used next-generation sequencing (NGS) of B cell transcripts
from the January 2011 time point to identify 10E8-lineage member sequences in both heavy
and light chains and to pair them phylogenetically [18]. Here we combined an additional
round of NGS from the same January 2011 time point with structure-function studies of germ-
line and mature 10E8 antibodies and of their maturation intermediates to approximate the
developmental pathway for the 10E8 lineage. The results provide insight into the nature of the
antigen that initially stimulated the 10E8 lineage, the extent of polyreactivity in the B cell




Sera and peripheral blood mononuclear cells (PBMCs) were obtained from an HIV-1-infected
donor (N152) enrolled in a clinical protocol approved by the Investigational Review Board in
the National Institute of Allergy and Infectious Diseases (IRB-NIAID). An IRB-NIAID
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approved consent form was provided to all donors, which was reviewed with all donors by a
NIAID clinician. Donor N152 provided written consent to use of these samples [18,21].
Antibody expression and purification
Codon-optimized genes corresponding to the 10E8 heavy and light chain intermediates were
synthesized with a 5’ secretion leader sequence and sub-cloned into the mammalian expression
vector pVRC-8400. Transient expression of the antibodies and variants was undertaken in
293F cells or 293 Expi cells as per manufacturer’s instructions (Life Technologies) by co-trans-
fection of equal amounts of the respective heavy and light chain plasmids. Antibody IgG’s were
purified from expression supernatants by capture with Protein A sepharose (Pierce) followed
by elution with low pH elution buffer (Pierce) and adjustment of eluate pH with use of Tris-Cl
(pH 8.0).
Antibody antigen binding fragments (Fabs)
The antigen binding fragments of 10E8 intermediates were prepared using endoproteinase
Lys-C (Roche) digestion as previously described [18]. Briefly, the protease was added at con-
centrations of 1:1,000 to 1:10,000 and the digestion undertaken at 37°C for 4–6 h. Protease
digestion reactions were stopped with protease inhibitor tablets (Roche) and cleaved products
were passed over a Protein A column to remove the Fc fragment.
Mutagenesis of 10E8 reverted gHv and gLv antibodies
10E8 gHv and gLv antibodies were prepared by using the assigned germline genes with the
fully mature CDR H3 sequence as defined in Huang et al.,[21]. Initial tests with this Vgene-
reverted antibody showed no neutralization against a set of HIV-1 pseudoviruses, while neu-
tralization was observed with a substantially reverted antibody with no mutations in the frame-
work regions of the antibody and with ten mutations in CDR H1 and CDR H2 and two
mutations in the CDR L1[7]. Initial neutralization tests using a fully reverted gLv antibody
combined with a heavy chain containing eight mutations in the CDR H2 and a fully mature
CDR H3 (10E8 8H) gave reasonable potency against a panel of eight pseudoviruses. Further
mutagenesis was carried out on this construct along with neutralization assays to identify a sin-
gle K52T mutation as sufficient to enable neutralization of seven out of eight of these strains
with reasonable potency. All mutagenesis experiments were performed by GeneImmune Bio-
technology (Maryland, US) using QuickChange II Site-directed mutagenesis Kit (Agilent Tech-
nologies, Santa Clara, US). The respective mutations were confirmed by DNA sequencing.
Antibody mutants were expressed by pairing with corresponding wild type partner chains fol-
lowing the same protocol described for wild type IgG expression. All antibodies were purified
by affinity chromatography using Protein A columns and eluted by IgG Elution Buffer (Pierce).
The antigen binding fragments (Fab) of all VRC01-class antibodies were generated by Lys-C
(Roche) digestion of IgG as previously described [22].
Crystallization, structure determination, and structural analysis
Antigen-binding fragments (Fabs) of 10E8 variants with V-gene regions reverted to genomic
origin for heavy-chain, but with mature light chain (termed here gHv/mature L) or with V-
gene regions reverted to genomic origin for heavy and light-chains (gHv/gLv), or with mature
heavy and light chains (mature H and L) were prepared and screened against 576 crystalliza-
tion conditions adapted from the commercially available Hampton (Hampton Research), Pre-
cipitant Synergy (Emerald Biosystems) [23], and Wizard (Emerald Biosystems) screens using a
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Cartesian Honeybee crystallization robot by the vapor diffusion method in sitting drops at
20°C. Initial crystal hits were manually reproduced in hanging drops by mixing 0.5 μl protein
complex solution with 0.5 μl reservoir solution.
Crystals of ligand-free mature H and L 10E8 Fab were obtained in a condition comprised of
6% PEG 8000, 25% Isopropanol, 0.1 M Imidazole pH 6.5, and were flash frozen in liquid nitro-
gen in mother liquor. Crystals of the gHv/mature L Fab were obtained in a condition com-
prised of 21% PEG 8000, 0.17M ZnAc, MES, pH6.0 and were flash frozen in liquid nitrogen in
mother liquor supplemented with 22% glycerol. Crystals of the gHv/gLv Fab were obtained in
a condition comprised of 15% PEG 8000, 10% Isopropanol, imidazole, pH 6.5 and were flash
frozen in liquid nitrogen in mother liquor supplemented with 15% ethylene glycol.
Diffraction data for all crystals were collected at a wavelength of 1.00 Å at beamlines SER
CAT ID-22 or BM-22 (Advanced Photon Source, Argonne National Laboratory). All diffrac-
tion data were processed using HKL-2000 [24]. Structures were solved with molecular replace-
ment using Phaser [25] and refinement of the structures was carried out using a cross
validation (Rfree) test set consisting of 5% of the data, using Phenix [26] with iterative rounds of
model building in Coot [27]. Structure validation was carried out using MolProbity [28].
The ligand-free 10E8 Fab structure was refined to a final Rfree value of 21.54% with 97.0% of
the residues in the favored region of the Ramachandran plot, and 0% outliers. The gHv/mature
L Fab structure was refined to a final Rfree value of 27.1% with 98.6% of the residues in the
favored region of the Ramachandran plot, and 0% outliers. The gHv/gLv Fab structure was
refined to a final Rfree value of 20.9% with 97.9% residues in the favored region of the Rama-
chandran plot, and 0% outliers. All structure figures were prepared using Pymol [29].
HIV-1 neutralization assays
Neutralization was measured using a panel of eight HIV-1 Env-pseudoviruses to infect TZM-
bl cells as previously described [30] (see S1 Table for details on HIV-1 isolate panel). Neutrali-
zation curves were fit using nonlinear regression on a 5-parameter Hill equation. The data
were calculated as a reduction in luminescence units compared with control wells, and reported
as half-maximum inhibitory concentration (IC50) in micrograms per milliliter for monoclonal
antibodies.
Sample preparation for 454 pyrosequencing
Samples for 454 pyrosequencing were prepared using cDNAs from Donor N152 PBMCs gen-
erated in a previous study [18]. Briefly, mRNA was extracted from 33 million PBMCs (Oligotex
kit, Qiagen), and reverse transcription was performed in multiple 35 μl-reactions, composed of
15 μl of mRNA, 3 μl of oligo(dT)12-18 at 0.5 μg/μl (invitrogen), 7 μl of 5x first strand buffer
(Invitrogen), 3 μl of RNase Out (Invitrogen), 3 μl of 0.1M DTT (Invitrogen), 3 μl of dNTP mix
(each at 10 mM), and 3 μl of SuperScript II (Invitrogen). Immunoglobulin gene-specific PCRs
were undertaken using 10 μl of the cDNA as template (equivalent of transcripts from 10 mil-
lion PBMCs), 5 μl HiFi Taq 10x reaction buffer (Invitrogen), 2 μl 50 mMMgSO4, 2 μl dNTP
mix (each at 10 mM), 2 μl gene-specific 5’-primer (S2 Table) at 25 μM, 2 μl of each 3’-primer at
25 μM, 1 μl DNA polymerase, and water to a final volume of 50 μl. The primers each contained
adaptor sequences (XLR-A or XLR-B) for subsequent 454 pyrosequencing. PCRs were initiated
at 95°C for 30 sec, followed by 25 cycles of 95°C for 30 sec, 58°C for 30 sec, and 72°C for 1 min,
followed by 72°C for 10 min. PCR products were gel purified (Qiagen) and phenol/chloroform
extracted. 454 pyrosequencing, instrumentation specifics, and initial data processing and
sequencing were carried out as previously described [18].
Developmental Pathway of Antibody 10E8
PLOSONE | DOI:10.1371/journal.pone.0157409 June 14, 2016 4 / 21
Bioinformatics analysis of 454 pyrosequencing-determined
antibodyomes
The bioinformatics pipeline developed in our previous studies [18] was used to process the 454
pyrosequencing data for antibodyome analysis. We have made some changes to the original
pipeline described below. As before, the pipeline consists of the following five steps: (i) filter
out reads with less than 300 nt; (ii) assignment of variable (V), diverse (D), and joining (J) gene
families and alleles to each sequence using an in-house implementation of IgBlast [31]
(sequences with E value> 10−3 for V or J gene assignment were rejected); (iii) template-based
error correction scheme, where 454 homopolymer errors in V, D (heavy chain only), and J
regions were detected and corrected based on sequence alignment to the respective germ-line
sequence; (iv) comparison with a set of template antibody sequences at both nucleotide and
amino acid levels using a global alignment module in ClustalW [32]; and (v) determination of
the nucleotide and amino acid sequences comprising the third complementarity-determining
region (CDR H3 or L3). A preliminary analysis of the processed data showed very few
sequences with the IGHD3-301 germline assignment which occurs in the mature heavy chain
10E8 sequence. We thus submitted all processed sequences containing the same V-germline
assignment as the heavy chain 10E8 sequence to the IMGT High-Vquest server (http://www.
imgt.org/IMGTindex/IMGTHighV-QUEST.html) [33]. This additional processing resulted in
a larger of pool of sequences with the IGHD3-301 germline gene assignment.
We used a series of bioinformatic sieves to enrich the pool of sequences containing the same
lineage characteristics as the mature 10E8 sequence for downstream phylogenetic analysis.
These sieves were applied to both the heavy and light chain processed NGS data sets and
removed any sequences that did not have the same germline gene assignments as in the mature
10E8 sequence. The first sieve was applied to both heavy and light chain NGS data sets and
removed all sequences that did not have the correct V germline assignment (IGHV3-15). A
second sieve was applied only the heavy chain and removed all sequences that did not have the
IGHD3-301 D-gene assignment. A third sieve was applied to both the heavy and light chain
data sets and removed all sequences that did not have the correct J germline gene assignment.
Once sieving was done using the germline gene assignments both, heavy and light chain data
sets were subjected to a second round of sieving using sequence signatures appearing in the
CDR3 sequence. The signature sequence for the heavy chain derives from the IGHD3-301
germline gene, YYDFWSGYYT, and appears in the mature 10E8 sequence. For the heavy chain
data set, sequences were sieved using the following sequence signature: Y[AD]FW[SG]GY,
where the “[]”indicates either of the two amino acids were present at that position. Thus any
sequence that contained either the full signature or a partial signature was retained for further
downstream processing. A similar sieve was applied to the germline filtered light chain data
set. However, since the number of sequences for the germline-sieved light chain data set was
large (149,325), we applied a CDR L3 length filter followed by the CDR L3 signature filter. The
length filter removed any sequence with a CDR L3 length (IMGT) shorter than 9 amino acids
or longer than 13 amino acids. The length sieve had little effect on reducing the total number
of sequences but did remove sequences residing outside the large contours. Application of the
CDR L3 signature sieve was effective at pulling out mature sequences only.
Phylogenetic analysis and the determination of heavy and light chain
intermediates
After sieving both the heavy and light chain NGS data sets, we generated maximum-likelihood
(ML) trees for both the germline-filtered and the CDR signature derived data sets. Before tree
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construction, sequences were vetted and corrected for any sequencing errors which couldn’t be
removed using our template-based correction algorithm.
For the heavy chain data set, we constructed two separate multiple sequence alignments
(MSA) from both the germline-derived sequences (235 sequences) and CDR H3 signature-
derived sequences (50 sequences). The alignments were then provided as input to construct a
maximum-likelihood phylogenetic tree using dnaml in the PHYLIP [34] package v3.69 (http://
evolution.genetics.washington.edu/phylip.html). The calculation was done with default param-
eters and the outgroup was set as the germline gene and the resulting tree visualized using Den-
droscope [35]. Intermediate sequences were corrected at nucleotide positions containing low
probability scores that introduced stop codons. Ambiguous nucleotide positions were esti-
mated based on the more mature sequences along the evolutionary pathway.
For the light chain data set, the number of plausible sequences for the CDR L3-derived data
set was large (149,301 sequences) and so we first partitioned the ensemble of sequences into
germline divergence bins separated by 0.5% units. A sequence from each bin was then ran-
domly selected and the total pool of sequences aligned and then provided as input for ML tree
construction using dnaml. In the event that any sequence contained an error (i.e., failed to
translate without a stop codon) that sequence was discarded and another sequence randomly
selected in its place. For the CDR L3 signature-sieved data set (513 sequences), all sequences
containing the SSRDKSGSR signature in the CDR L3 were binned in a similar fashion aligned
and then used as input for dnaml.
To evaluate the fitness of each UCA sequence, we looked at a number of sequence properties
that we felt would best characterize the most plausible maturation pathway. The properties
included the number of intermediates in the ML tree, the total number of reversions between
the UCA and mature 10E8 and the number of N-type additions at the junctions for both heavy
and light chain UCA sequences (see S3 and S4 Tables). The junctional analysis was performed
using the program JOINSOLVER [35] and is available through a web-interface (http://
joinsolver.niaid.nih.gov).
Surface-Plasmon Resonance (SPR) binding analysis
A Biacore T200 (GE Healthcare) was used to assess binding affinity of 10E8 maturation inter-
mediates to a gp41 MPER peptide. A biotinylated peptide composed of residues 656–683 of the
gp41 MPER (RRR-NEQELLELDKWASLWNWFDITNWLWYIR-RRK-biotin) was coupled to
a biacore SA chip and 10E8 intermediate Fabs flowed over as analytes at two-fold serial concen-
trations that ranged from 15.6–500 nM (UCA), 3.9–500 nM (pI1), 15.6–125 nM (pI2, pI3, and
10E8 mature), and 31.25–500 nM (17b). Association and dissociation phases extended up to 5
min, at a flow rate of 30 μl/min.
Liposomes
Liposomes were prepared as previously described [15] and reflected lipid ratios predicted to be
present in the HIV-1 lipid bilayer. A 9:9:18:20:45 molar ratio of 1,2-dioleoyl-sn-glycero-
3-phosphatidylcholine (DOPC), 1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)]
(DOPG), egg sphingomyelin (SM), 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine
(DOPE), and cholesterol (CHOL), respectively, was used. All lipids were purchased from
Avanti Polar Lipids, Inc. MPER proteoliposomes were embedded with an MPER peptide span-
ning gp41 residues 659–683 as previously described [15], to a final concentration of 16 μM.
The final concentration of phospholipid in all liposomes was 50 mM.
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Liposomal MPER competition ELISA
A biotinylated MPER peptide corresponding to residues 656–683 of gp41 MPER (RRR-NE-
QELLELDKWASLWNWFDITNWLWYIR-RRK-biotin) was captured at 4°C overnight on
neutravidin-coated ELISA plates (Pierce) at a concentration of 0.1–0.2 μM. Plates were
washed in phosphate-buffered saline (PBS) blocked for 1 hr at 25°C in PBS supplemented
with 5% fetal bovine serum plus 2% dried milk. 100 μl of each respective antibody in blocking
buffer was incubated alone or in presence of respective MPER competitors at 5 fold serial
concentrations ranging from 1x10-3 to 16 μM for 1 hr at 25°C. These mixtures were added to
the wells coated with MPER peptide and incubated for an additional hr at 25°C. The plates
were then washed in PBS and 100 μl of mouse horseradish peroxidase (HRP)-conjugated
anti-human Fc IgG added at 1:10,000 dilution in blocking buffer to all wells. After 1 hr of
incubation at 25°C, plates were washed and a Bio-Rad HRP substrate detection kit used to
detect bound secondary antibody. The reactions were stopped by adding 0.5 N sulfuric acid,
and optical densities were measured at 450 nm. In each case, experiments were run in
duplicate.
Antibody autoreactivity assays
Indirect immunofluorescence binding of rMAbs to HEp-2 cells (Inverness Medical Profes-
sional Diagnostics, Princeton, NJ) was performed as described previously (16). Briefly, 20 μl
of antibody at 25 μg/ml was placed on a predetermined spot on the surface of an ANA HEp-2
kit slide, incubated for 25 min at room temperature, washed, and developed with 20 μl of goat
anti-human Ig-FITC at 20 μg/ml (Southern Biotech, Birmingham, AL) for 25 min. For images
of murine MAb 13D5, goat anti-mouse Ig-FITC at 20 μg/ml (Jackson ImmunoResearch, West
Grove, PA) was used. Incubations were performed in humid chambers in the dark. Slides
were washed and dried; a drop of 33% glycerol was placed on each spot prior to the fixing of
coverslips. Images were taken on an Olympus AX70 with SpotFlex FX1520 charge-coupled
device (CCD) with a UPlanFL 40x (numerical aperture, 0.75) objective at 25°C in the FITC
channel using SPOT software. All images were acquired for the time specified in the figure leg-
end. Image layout and scaling were performed in Adobe Photoshop without image manipula-
tion. Monoclonal antibody reactivity to SSA/Ro, SS-B/La, Sm, ribonucleoprotein (RNP), Jo-1,
double stranded DNA, centromere B, and histone was measured by using the AtheNAMulti-
Lyte ANA kit (Alere Inc., Waltham, MA) as previously described [19]. Antibodies were incu-
bated with AtheNA beads for 30min at final concentrations of 50, 25, 12.5 and 6.25 μg/ml.
Beads were washed, incubated with secondary and read on the Luminex platform. Samples
were analyzed using AtheNA software. Cardiolipin reactivity was measured using the Quanta
Lite ACA IgG III kit (Inova Diagnostics, Inc. San Diego, CA) by diluting antibodies to final
concentrations of 50, 25, 12.5 and 6.25 μg/ml in sample diluent and assaying per manufactur-
er’s specifications.
Data
10E8 crystal structures determined here have been deposited with the Protein Data Bank
(PDB) under PDB codes (5JNY, 5JO5, 5JR1). Functionally characterized sequences of antibody
intermediates have been deposited with Genbank under accession codes KX147288-
KX147295. NGS data from donor N152 obtained with the modified heavy chain primers have
been deposited with the Short Reads Archives (SRA) under SRP018335.
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Results
Structures of 10E8 variants with VH regions reverted to germline
To gain insight into the structural changes that accompanied maturation of the 10E8 antibody
from B cell recombinant to mature antibody, we determined crystal structures of the ligand-
free antigen-binding fragments (Fabs) of the mature 10E8 antibody and two germline variants:
(i) a V-gene reverted version (gHv/gLv), in which both the heavy chain and light chain variable
regions were reverted to their germline origin, and (ii) a heavy chain-only version (gHv/mature
L), in which only the heavy chain-variable region was reverted to its germline origin and paired
with the mature 10E8 light chain. X-ray diffraction data from these three structures extended
to 3.05, 1.70, and 1.60 Å respectively, and they were solved by molecular replacement and
refined to Rwork/Rfree of 18.8/21.5, 23.7/27.1, and 19.4/20.9% for ligand-free mature H and L,
gHv/gLv, and gHv/mature L versions of 10E8, respectively (Table 1). Electron density for an
Table 1. Crystallographic data collection and refinement statistics.
10E8 mature H and L 10E8 gHv/gLv 10E8 gHv/mature L
PDB accession code 5JNY 5JO5 5JR1
Data collection
Space group P63 P21 P212121
Cell constants
a, b, c (Å) 248.6, 248.6, 54.3 115.3, 65.3, 128.1 68.8, 77.9, 85.0
α, β, γ (°) 90.0,90.0,90.0 90.0,90.0,90.0 90.0,90.0,90.0
Wavelength (Å) 1.00 1.00 1.00
Resolution (Å) 50.0–3.04 (3.16–3.05)* 50.0–1.50 (1.62–1.55; 1.55–1.50) 50.0–1.60 (1.72–1.66;1.66–1.60)
Rmerge (%) 22.1 (68.4) 12.7 (54.4; 68.7) 13.0 (90.2; 95.2)
I / σI 10.4 (2.09) 7.87 (1.63; 1.13) 9.83 (2.14; 1.38)
Completeness (%) 99.7 (98.3) 100.0 (100.0; 100.0) 84.6 (89.2;83.4)
Redundancy 10.6 (7.6) 4.0 (3.9; 3.8) 4.7 (4.3; 3.4)
Refinement
Resolution (Å) 32.8–3.05 (3.16–3.05) 38.47–1.7 (1.76–1.70) 37.3–1.6 (1.63–1.60)
No. reflections 37411 (3610) 204611 (6502) 51383 (2443)
Rwork / Rfree (%) 18.76/21.54 23.7/27.1 19.4/20.9
No. atoms
Protein 6727 13077 3323
Ligand/ion 25 0 5
Water 16 1700 308
B-factors (Å2)
Protein 56.2 25.57 31.64
Ligand/ion 49.6 n/a 32.00
Water 38.0 32.3 37.18
R.m.s. deviations
Bond lengths (Å) 0.003 0.005 0.012
Bond angles (°) 0.720 0.774 1.232
Ramachandran
Favored (%) 97.00 98.54 97.9
Allowed (%) 3.00 1.46 2.08
Disallowed (%) 0.0 0.0 0.0
*Values in parentheses are for highest-resolution shell(s).
doi:10.1371/journal.pone.0157409.t001
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unknown ligand was observed adjacent to residue Ser 100c in the CDR H3 for the gHv/mature
L 10E8 Fab.
Comparison of the structure of the mature uncomplexed Fab with that of the previously
determined structure of mature 10E8 bound to its gp41 epitope [8] showed minimal changes
in the complementarity-determining regions (CDRs), with root-mean-square deviation (rmsd)
for the entire Fv domain of 0.2 Å (Fig 1A). By contrast, the structure of the gHv/gLv Fab
showed substantial changes in both the heavy chain 2nd and 3rd CDRs (CDR H2 and H3). All
four residues at the top of the gHv/gLv CDR H2 differed in Cα-positions by over 1 Å from the
mature unbound structure, and much of the CDR H3 was disordered (Fig 1B and S1 Fig). Dif-
ferences were also seen in the gHv/mature L structure, though in this case, the CDR H3 was
fully ordered. Thus maturation from germline to mature 10E8 affects the structure of the CDR
H2 and H3 regions, and these structural changes occur primarily as a result of somatic hyper-
mutation of the heavy chain V gene.
Fig 1. Structures of mature10E8 antibody and its genomic revertants. (A) (left) Mature antibody-MPER
complex (PDB ID: 4G6F). The MPER peptide is colored red and the mature 10E8 antibody heavy chain in
pink and light chain in gray. (right) The ligand-free 10E8 Fab is structurally aligned to the 10E8-MPER
complex structure with an overall Cα r.m.s.d of 0.2 Å. (B) (left) Ligand-free structures of germline-reverted
gHv/gLv and (right) partially reverted gHv/mature L structurally aligned to the mature 10E8 with an overall Cα
r.m.s.d of 0.2 Å. Structural differences with Cα r.m.s.d. greater than 2.0 Å are colored in red and displayed in
stick representation.
doi:10.1371/journal.pone.0157409.g001
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Mutational analysis of CDR H2
To delineate the functional importance of specific residues mutated during VH-gene matura-
tion, we analyzed sequence differences between mature and germline sequences. A cluster of
eight out of nine residues were altered by SHM in the CDR H2 (Fig 2A). Reversion of the 29
and 18 mutations in the heavy and light V-gene regions, respectively, abolished neutralization
(Fig 2A, 10E8 gHv/gLv), whereas retaining only the eight SHM-derived mutations in the CDR
H2 retained neutralization for seven of eight diverse HIV-1 strains (Fig 2A, 10E8 8H). A single
K52T mutation in CDR H2 allowed the otherwise V gene-reverted 10E8 to neutralize seven of
eight strains (Fig 2A, 10E8 1H); while including a second mutation G55W increased potency
to near wild-type levels (Fig 2A, 10E8 2H). (Antibody numbering is provided in Kabat nomen-
clature [36].)
Analysis of residue K52 indicated a clash with the MPER epitope at the highly conserved
Phe 673 residue (Fig 2B); W55, in contrast, appears to stabilize the CDR H2 by forming hydro-
gen bonding interactions with residue 52b (Lys in germline and Pro in mature antibody; the
“b” in 52b refers to the 2nd insertion after residue 52 in Kabat nomenclature) allowing residue
53 (Asp or Glu) to hydrogen bond with the main chain N of Trp 672 of the MPER. Thus,
Fig 2. Analysis of 10E8 somatic hypermutation identifies critical K52Tmutation. (A) Summary of CDR H2 somatic
hypermutation and 10E8 neutralization. Total mutations from germline are indicated for both heavy and light chains. The CDR H2
germline sequence is shown colored blue with somatic mutations indicated in black. Viruses neutralized with an IC50 < 50 μg/ml
or < 1 μg/ml are indicated (see S1 Table for details on HIV-1 isolate panel). (B) Superposition of mature 10E8 complex structure and
10E8 gHv/gLv. Coloring is the same as in Fig 1. (C) Expanded view of CDR H2. Residues that were mutated and gave improved
10E8 gHv/gLv neutralization levels are shown in stick representation. Residues Phe 673 (MPER) and Lys 52 (10E8 gHv/gLv) overlap
and are not compatible with binding due to steric clashing.
doi:10.1371/journal.pone.0157409.g002
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critical SHM alterations for MPER recognition appear to be located in CDR H2 with the K52T
mutation mediating the most significant change in recognition.
Next-generation sequencing of B cell transcripts from donor N152
To identify 10E8 lineage members, we previously performed NGS of B cell transcripts from
donor N152 [8], the source of the broadly neutralizing antibody 10E8, using polymerase chain
reaction (PCR) to amplify IgG-heavy chain sequences from the IGHV3 family and to amplify
IgG-light chain sequences from the IGLV3 family [18]. Because the 10E8 lineage heavy chain
transcripts were not highly prevalent [18] and as a control for the error-prone nature of NGS,
we performed a second set of PCR reactions for the 10E8 heavy chain to identify additional
lineage members and to provide replicate data for error analysis (see methods and S2 Fig).
454 pyrosequencing was used to sequence the PCR products that were generated by an iden-
tical set of primers as the initial reactions from our previous study [18] with the exception of
the 5’ heavy chain primer, XLR_A_VH3-15, which was modified to better correspond to VH3-
15 antibody gene sequences (S2 Table). NGS generated a total of 647,551 reads of which 91%
had sequence lengths greater than 300 nucleotides (S2 Fig). In our previous study [18], we
obtained 843,084 heavy chain reads of which 98% had sequence lengths greater than 300 nucle-
otides. A comparison between the new and published NGS heavy chain data sets revealed the
new data set to have a broader distribution of germline gene assignments.
Bioinformatics identification of 10E8 lineage heavy-chain transcripts
A total 96,178 full-length heavy chain sequences were assigned to IGHV3-15, of which 7,923
were derived from IGHD3-3, and 235 additionally derived from IgHJ1 and IgHJ2 (Fig 3A).
Inspection revealed that a substantial number of these sequences contained a Y[AD]FW[SG]
GYmotif (bracketed pairs of amino acids signify a single position at which either amino acid
appeared) in the CDR H3 region, which comprised an essential part of the 10E8 paratope and
was remarkably similar to the 01 allele of IGHD3-3 (YYDFWSGYT). We therefore used the
presence of this motif in the CDR H3 region to identify potential heavy chain-lineage members
(Fig 3A, right most panel).
We constructed maximum-likelihood (ML) phylogenetic trees based on the CDR H3 signa-
ture-selected sequences (H3 signature tree) (Fig 3B), as well as on all sequences with the
expected 10E8 V, D, and J origin genes (VDJ tree) (S3 Fig). While the VDJ tree defined over 30
intermediates between the potential UCA and mature 10E8, the UCA derived from this tree
required 27 N-nucleotide additions and 64 reversions where each reversion comprises a nucle-
otide that mutates by SHM, but then reverts back to the original nucleotide during the pre-
dicted maturation pathway (S3 Table). In contrast, the H3 signature tree defined over 9
intermediates and the derived UCA required 20 N-nucleotide additions and 10 reversions (Fig
3C and S3 Table). Parsimony analysis therefore suggests the H3 signature tree to provide a
more likely representation of 10E8 heavy chain development. Intermediates I1-h through I9-h,
corresponding to each of the nodal points in the phylogenetic tree separating UCA from
mature 10E8, were estimated and all nucleotide positions for each intermediate could be
uniquely defined with the exception of a single position in the framework-3 region of interme-
diate I1-h (Fig 3C).
Although the additional set of 454 data did provide more sequences, as shown in the H3 sig-
nature tree, both data sets combined provide few low-divergence heavy chain reads making the
determination of the UCA and I1-h intermediates imprecise (Fig 3B). In total, 73% of the
heavy chain reads in the H3 signature tree appeared in both sets with the remaining sequences
being split between the two sets. While the new NGS data provided a few more low-divergence
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Fig 3. 10E8 heavy chain ontogeny: lineagemembers and calculated intermediates. (A) Selection of 10E8 clonal variants by
computational sieving. Identity/divergence plots showing the results of sieving on V gene (left), V, and J genes (panel 2), V, D, and J genes
(panel 3), and CDR H3 signature (panel 4). (B) Phylogenetic tree based on CDR H3 signature-selected sequences; signature represents the
overlap between the germline gene (HD3-3*01) and the mature 10E8 heavy chain sequence. Terminal branches were labeled to indicate
which dataset the terminating sequence derives from. Branches ending ‘O’ indicate the sequence is derived from the published data set.
Branches ending in ‘N’ indicate the sequence is derived from the new data set. And branches ending in ‘B’ indicate that the sequence can be
found in both data sets. The threshold for inclusion into a data set was set at >97.5% nucleotide sequence identity and >98% alignment
coverage. The coloring scheme for the ML tree was adapted from Zhu et al., [18]. Blue circles indicate nodal points on the tree. (C)
Sequences of phylogenetically inferred developmental intermediates compared to mature 10E8 and constituent germline genes. Numbers
appearing in parenthesis on the left side of the alignment indicate the number of identical residues to the germline V gene. The undefined
residue labeled ‘X’ in I1-h was changed to a phenylalanine for pairing and functional analysis.
doi:10.1371/journal.pone.0157409.g003
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reads than the published data set [18], none of the new low-divergence reads were duplicates.
Sequences that appeared in both data sets clustered in the lower half of the ML tree (Fig 3B).
Bioinformatics identification of 10E8 lineage light-chain transcripts
A total of 235,980 full-length light chain sequences were assigned to IGLV3-19, of which
149,325 were derived from IGLJ3 and IGLJ2. As we did not expect large insertions or deletions,
we additionally analyzed sequences with CDR L3 lengths from 9 to 13 amino acids (IMGT
nomenclature)–reducing the total number of sequences to 143,301 (Fig 4A). Inspection of the
light chain sequence of mature 10E8 as well as the light chain sequences we previously identi-
fied to be part of the lineage [18] revealed all contain a SSRDKSGSR sequence motif in the
CDR L3 region. We therefore used the presence of this 9-mer sequence as a sieve to identify
potential light chain-lineage members (Fig 4A, right most panel).
We used the sieved light chain sequences to construct two ML phylogenetic trees: one based
on the CDR L3 signature-selected sequences (L3 signature tree) (S4 Fig), and one based on the
length-sieved sequences with expected 10E8 V and J origin genes (VJ tree) (Fig 4B). As there
were too many length-sieved sequences to analyze by maximum likelihood, we sorted these
sequences into 0.5% SHM divergence bins, and constructed a phylogenetic tree from randomly
selected binned sequences. The L3 signature and the VJ tree produced different overall topolo-
gies with the former having only three nodal points (labeled as I1-l through I3-l) between the
UCA and the mature 10E8 light chain sequence (S4 Fig). In contrast, the VJ tree has twice as
many nodal points between the calculated UCA and the mature 10E8 light chain sequence (Fig
4B). While both the VJ tree and L3 signature tree had almost no nucleotide reversions, the cal-
culated UCA from the L3 signature tree had 14 N-nucleotide additions in comparison to the
UCA belonging to the VJ tree which had only 1 N-nucleotide addition (S4 Table). While the
L3 signature tree was slightly more parsimonious than the VJ tree it lacked a well-defined UCA
with 4 amino acid differences when compared to the IGLV3-19 germline gene (Fig 4C and S4
Fig).
Pairing of heavy and light chain intermediates
NGS of antibodies that utilize separate heavy and light PCR reactions removes heavy-light
pairing information. However, we previously showed that phylogenetic analyses could be used
to pair antibodies of the 10E8 lineage, and that such phylogenetically paired antibodies exhibit
reduced polyreactivity [18]. Based on our prior work, we attempted to use the topological
information derived from the ML trees to obtain an approximate pairing for the heavy and
light chain intermediates between the H3 signature tree and the VJ tree.
The UCA and mature 10E8 define two unambiguous pairs. We paired the first intermediate
sequence from each phylogenetic tree to create paired intermediate pI1 (10E8-pI1), as the early
development of the lineage is of interest and I1 was the closest intermediate to UCA (Fig 5).
Intermediate I2 left a number of possible nodal pairings between it and mature 10E8. One pos-
sibility would be to pair comprehensively all identified transcripts; however, as such pairing is
only an approximation of 10E8 development, we decided that for a first assessment, we would
approximate 10E8 development with only two additional pairings: pI2 (10E8-pI2, pairing I3-h
and I3-l) and pI3 (10E8-pI3, pairing I5-h and I6-l) (Fig 5). The pairings were chosen to main-
tain the phylogenetic structure that previously displayed reduced polyreactivity [18].
Functional assessment of 10E8 and maturation intermediates
The UCA, three 10E8 pairings (pI1, pI2 and pI3), along with mature 10E8 were expressed,
purified and assessed for function. When tested for neutralization on eight diverse HIV-1
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isolates, no neutralization was observed for UCA or pI1, while pI2 neutralized 7 or 8 strains,
and pI3 and mature 10E8 showed increased potency against all 8 strains (Fig 6A). To assess
functionality of the 10E8 maturation intermediates, fragments of antigen binding (Fabs) of
each of the intermediates were produced and then tested in surface plasmon resonance (SPR)
Fig 4. 10E8 light chain ontogeny: lineagemembers and calculated intermediates. (A) Selection of 10E8 clonal variants by computational
sieving. Identity/divergence plots showing the results of sieving on V gene (left), V, and J genes (panel 2), CDR L3 length between 9 and 12
residues (IMGT numbering) (panel 3), and CDR L3 signature (panel 4). (B) Phylogenetic tree based on CDR L3 length-selected sequences. To
construct a phylogenetic tree from >105 sequences, representative sequences were selected randomly from bins of 0.5 divergence units (as
shown in left inset). The numbers in parenthesis at the end of each branch correspond to the total number of clones that share >99% nucleotide
sequence identity and 99% alignment coverage. Branches terminating without numbers indicate that the sequence has more than 10 clones with
>99% nucleotide sequence identity and 99% alignment coverage. The coloring scheme for the ML tree was adapted from Zhu et al., [18]. Blue
circles indicate nodal points on the tree. (C) Sequences of phylogeneticaly inferred developmental light chain intermediates compared to mature
10E8 and constituent germline genes. Numbers appearing in parenthesis on the left side of the alignment indicate the number of identical
residues to the germline V gene.
doi:10.1371/journal.pone.0157409.g004
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for binding to a peptide corresponding to residues 656–683 of the gp41 MPER (Fig 6B). Kinetic
binding analysis revealed that the UCA, pI1 through pI3, and mature 10E8 bound gp41 MPER
to varying levels. Both UCA and pI1 showed weak binding to the MPER peptide, although the
signal observed was greater than that observed for a non-cognate control antibody 17b,
whereas pI2 through mature 10E8 showed strong binding with decreasing off-rates (Fig 6B).
Fig 5. Pairing of heavy and light 10E8 intermediates. (A) Heavy (top) and light (bottom) phylogenetic trees with pairing of inferred
intermediates indicated by dashed lines. Intermediate pairing based on tree structure and considerations from polyreactivity (see text and
[18]). (B) Heavy chain UCA, intermediates and mature sequences. (C) Light chain UCA, intermediates and mature sequences.
doi:10.1371/journal.pone.0157409.g005
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Fig 6. Functional characteristics of 10E8 UCA andmaturation intermediates. (A) Neutralization on eight diverse HIV-1 isolates (see S6 Table for
details on HIV-1 isolate panel). (B) Sensogram profiles shown represent two-fold serial dilutions of Fab analyte starting at top concentrations of 500 nM
for UCA, pI1, and 17b, or 125 nM for pI2, pI3 and 10E8 mature, through to final concentrations of 3.9–31.25 nM. (C) ELISA assessment of MPER-
liposome recognition. Shown are bare liposome (left) and MPER proteoliposome (right) competiton ELISA assays for antibody recognition of a soluble
MPER peptide captured on a plate. Binding of 10E8 mature and pI3 antibodies to soluble MPERwas effectively competed by MPER proteoliposomes in
this assay. (D) Hep2 cell assessment of autoreactivity. (E) Structural models of 10E8 showing location and degree of somatic hypermutation by
intermediate. Structural models of 10E8 intermediate antibodies shown in ribbon representation showing the location of resides mutated from the UCA
as spheres and colored according to paired intermediate. The degree of somatic mutation for each 10E8 intermediate is given below each structure
model with % nucleotide and % amino acid change from the germline VH gene and also for the calculated UCA gene.
doi:10.1371/journal.pone.0157409.g006
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As functional recognition of the MPER appears to require binding in a lipid context [15],
we also tested recognition of 10E8 variants to MPER utilizing an ELISA-based liposome com-
petition assay. A biotinylated MPER peptide corresponding to residues 656–683 of gp41 was
captured on neutravidin coated ELISA plates, and binding of the 10E8 maturation intermedi-
ates to captured peptide was assessed directly and then in the competitive presence of MPER-
embedded proteoliposomes or bare liposomes. While binding of 10E8 UCA and pI1 to cap-
tured MPER peptide was too weak to detect in the direct binding assay (S5 Fig), and thus their
corresponding MPER-lipid binding characteristics also could not be assessed, 10E8 mature,
pI2 and pI3, all showed detectable binding to the captured soluble peptide, as did non-neutral-
izing MPER-specific antibody 11F10 that was used as a negative control [37] (S5 Fig). Addition
of MPER-embedded proteoliposomes as a competitor revealed that only the 10E8 mature and
pI3 antibodies could be effectively competed, while the binding of pI2 and 11F10 could not
(Fig 6C). None of the antibodies were successfully competed for binding to soluble peptide by
bare liposomes (Fig 6C). These results suggest that the capacity of paired 10E8 intermediates to
recognize MPER in a lipid-context is a trait that appears to have arisen later in the maturation
pathway, from pI3 and beyond.
We next addressed whether paired 10E8 intermediates were reactive with self-antigens.
While mature antibody 10E8 has previously been shown to lack such auto-reactivity [8,18], we
sought to determine whether this trait also applied to the paired intermediates. HEp-2 epithe-
lial cell staining (Fig 6D) combined with examination of reactivity with a panel of anti-nuclear
antigens (ANA) (S6 Fig) revealed an overall absence of reactivity with self-antigens, while con-
trol antibodies 2F5 and 4E10 exhibited high degrees of autoreactivity (Fig 6D, S6 Fig, S5
Table). These results suggest that 10E8 and its ancestral maturation intermediates lack reactiv-
ity with self-antigens from inferred inception, despite the capacity in some cases to recognize
MPER in a lipid context.
Discussion
The developmental pathways of broadly HIV-1-neutralizing antibodies provide insight into
their recombination and maturation and, along with studies of virus-antibody co-evolution,
can yield potential strategies for elicitation of similar highly desired antibodies [5,7,38,39].
Prior studies delineating antibody ontogenies have generally employed analysis of B cell immu-
noglobulin transcripts longitudinally sampled from time of infection antibodies [5,7]. How-
ever, such longitudinal data is not available for many broadly neutralizing antibodies. One of
these is antibody 10E8, for which samples were collected from only two time points, January
and June, 2011. We focused on the January 2011 time point, as it was earlier and was the time
point from which 10E8 was isolated through B cell culture. Here we describe a strategy through
which we gain insight into the ontogeny of 10E8 from a single time point. Our study highlights
the ability to use information from structure, NGS, and function, coupled with tools such as
parsimony, bioinformatics sieving, and maximum likelihood, to infer an approximate develop-
mental pathway from a single time point.
The 10E8 antibody is highly mutated (~21% SHM on the heavy chain) and NGS from a
cross-sectional time point requires sufficient sampling and a sufficient population of memory
B cells expressing low-divergence sequences. In the current study, each heavy chain data set
had few low-divergence sequences from the 10E8 lineage. This resulted in inferred UCA and
intermediate sequences which were ambiguous, and we resolved this ambiguity through parsi-
mony analysis (S3 and S4 Figs). Additionally, the presence of an unmutated stretch of residues
in the CDR H3 region allowed us to identify the HD3-301 germline D gene as being substan-
tially conserved from UCA to mature 10E8.
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The most parsimonious ontogeny for 10E8 development revealed early mutations in lineage
sequences such that by pI1, K52 had changed to a threonine and CDR H3 had incorporated E-
>K at position 97 and double-proline alterations. Despite these early changes, the functional
characteristics of UCA and pI1 were similar (Fig 6A–6C). By pI2 HIV-1 neutralization and
tight MPER peptide binding were observed, but not the ability to bind MPER in the liposome
context (Fig 6A–6C). Comparison of the CDR H3 sequences of pI2 and pI3 reveal one differ-
ence that could underlie this result, a histidine residue at position 98 in pI2 versus a tyrosine at
this position in pI3. The charged nature of histidine might reduce recognition in the lipid con-
text, though we cannot exclude the possibility that other sequence differences outside of the
CDR H3 loops of the two variants play a role in enabling lipid-context recognition. Overall,
MPER peptide affinity correlated with neutralization to a greater degree than binding MPER in
the liposome context.
Our findings with the 10E8 lineage have a number of implications for vaccine design. First,
UCAs may have substantial clashes with antigen (Fig 2). Lineage analysis suggests that these
need to be resolved early in development, and it appears that this can be accomplished by
SHM. Second, the 10E8 lineage develops weak affinity for soluble MPER peptide early.
Although we were unable to quantify the binding affinity by SPR for UCA and pI1, binding
was clearly above background. While weak UCA affinity has been observed previously, the
priming antigen for MPER-directed lineages was unclear; here we show that for 10E8 the prim-
ing antigen appears to be soluble portions of the MPER. Third, affinity for MPER in the lipo-
some context appeared late at pI3, with pI2 able to neutralize despite poor binding in the
liposome context. Thus, either the liposomal MPER binding assay was insensitive to weak lipo-
some-context binding, or liposome binding only occurs later in development. Altogether, the
10E8 lineage information obtained from a single time point thus provides a likely developmen-
tal pathway that should inform rational vaccine design efforts.
Supporting Information
S1 Fig. B factor analysis of ligand free 10E8 structures. Crystal structures of the (A) 10E8
gHv/gLv (B) 10E8 gHv/Mature L and (C) 10E8 mature are displayed in B factor putty repre-
sentation colored from blue to red and with larger and smaller putty size based on atomic B
factors scaled from 0 to 40 Å2.
(TIF)
S2 Fig. Bioinformatics pipeline processing of donor N152 454 Pyrosequencing datasets.
(A) Read length distribution for published heavy chain NGS data set and the distribution of
germline genes associated with reads larger than 300 nt. (B) Read length distribution for
unpublished heavy chain NGS data set and the distribution of germline genes associated with
reads larger than 300 nt. (C) Read length distribution for published light chain NGS data set
and the distribution of germline genes associated with reads larger than 300 nt. Bars colored in
blue denote the germlines of interest.
(TIF)
S3 Fig. 10E8 heavy chain ontogeny: lineage members and calculated intermediates. (A) ML
phylogenetic tree based on VDJ-sieve-selected sequences. (B) Sequences belonging to phyloge-
netically inferred developmental heavy chain intermediates compared to mature 10E8 and con-
stituent germline genes. The coloring scheme for the ML tree was adapted from Zhu et al., [18].
Blue circles indicate nodal points on the tree. Numbers appearing in parenthesis on the left
side of the alignment indicate the number of identical residues to the germline V gene.
(TIF)
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S4 Fig. 10E8 light chain ontogeny: lineage members and calculated intermediates. (A) Phy-
logenetic tree based on CDR L3 signature sieve-selected sequences. To select sequences for ML
tree construction, representative sequences were selected randomly from bins of 0.5 divergence
units (as shown in left inset). The coloring scheme for the ML tree was adapted from Zhu et al.,
[18]. Blue circles indicate nodal points on the tree. (B) Sequences of phylogeneticaly inferred
developmental light chain intermediates compared to mature 10E8 and constituent germline
genes. Numbers appearing in parenthesis on the left side of the alignment indicate the number
of identical residues to the germline V gene.
(TIF)
S5 Fig. Direct binding of 10E8 variants to soluble MPER peptide. Shown are ELISA profiles
of antibody variants binding to a biotinylated MPER peptide captured on neutravidin coated
plates. Profiles are colored as listed in figure legend. 10E8 UCA and pI1 did not show detectable
binding in this format.
(TIF)
S6 Fig. Antinuclear autoantigen (ANA) reactivity for UCA and intermediates pI1-pI3.
(TIF)
S1 Table. IC50 values (μg/ml) on a panel of eight viruses for 10E8 revertant and CDR H2
mutants.
(DOCX)
S2 Table. PCR primers used to prepare samples for 454 pyrosequencing analysis of donor
N152.
(DOCX)
S3 Table. Parameters used to evaluate the fitness of each maturation pathway derived from
heavy chain sequences.
(DOCX)
S4 Table. Parameters used to evaluate the fitness of each maturation pathway derived from
light chain sequences.
(DOCX)
S5 Table. Cardiolipin reactivity for paired heavy and light intermediates.
(DOCX)
S6 Table. IC50 values (μg/ml) on a panel of eight viruses for pairing of inferred heavy and
light chain antibody sequences.
(DOCX)
Acknowledgments
We thank B. B. Barnabas, G. G. Bouffard, S. Y. Brooks, H. Coleman, L. Dekhtyar, X. Guan,
J. Han, S. Ho, R. Legaspi, Q. L. Maduro, C. A. Masiello, J. C. McDowell, C. Montemayor,
M. Park, N. L. Riebow, J. Rosarda, K. Schandler, B. Schmidt, C. Sison, R. Smith, S.
Stantripop, J. W. Thomas, P. J. Thomas, M. Vemulapalli, A. C. Young and J. C. Mullikin (PI,
mullikin@mail.nih.gov) for 454-pyrosequencing at the NIH Intramural Sequencing Center
(NISC), J. Blinn at the Duke Vaccine Institute for assistance with testing antibody autoreactiv-
ity, J. Stuckey for assistance with figures, and members of the Structural Biology Section and
Structural Bioinformatics Core, Vaccine Research Center, for discussions or comments on the
manuscript.
Developmental Pathway of Antibody 10E8
PLOSONE | DOI:10.1371/journal.pone.0157409 June 14, 2016 19 / 21
Author Contributions
Conceived and designed the experiments: CS GOMGJ LS PDK. Performed the experiments:
CS GOMGJ BZ YY KM RP JE KEL SMA NSL JCM. Analyzed the data: CS GOMGJ BZ BFH
JRM LS PDK. Contributed reagents/materials/analysis tools: JH MC. Wrote the paper: CS GO
MGJ LS PDK.
References
1. Hraber P, SeamanMS, Bailer RT, Mascola JR, Montefiori DC, et al. (2014) Prevalence of broadly neu-
tralizing antibody responses during chronic HIV-1 infection. AIDS 28: 163–169. doi: 10.1097/QAD.
0000000000000106 PMID: 24361678
2. Liu J, Yue J, Wu S, Yan Y (2007) Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE
strains circulating in Fujian Province, China. Arch Virol 152: 1799–1805. PMID: 17619115
3. Haynes BF, Kelsoe G, Harrison SC, Kepler TB (2012) B-cell-lineage immunogen design in vaccine
development with HIV-1 as a case study. Nature biotechnology 30: 423–433. doi: 10.1038/nbt.2197
PMID: 22565972
4. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, et al. (2013) Rational HIV immunogen design to tar-
get specific germline B cell receptors. Science 340: 711–716. doi: 10.1126/science.1234150 PMID:
23539181
5. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, et al. (2013) Co-evolution of a broadly neutralizing HIV-1
antibody and founder virus. Nature 496: 469–476. doi: 10.1038/nature12053 PMID: 23552890
6. Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, et al. (2016) Maturation Pathway from Germline to
Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell 165: 449–463. doi: 10.1016/j.cell.2016.02.022
PMID: 26949186
7. Doria-Rose NA, SchrammCA, Gorman J, Moore PL, Bhiman JN, et al. (2014) Developmental pathway
for potent V1V2-directed HIV-neutralizing antibodies. Nature 509: 55–62. doi: 10.1038/nature13036
PMID: 24590074
8. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose N, et al. (2012) Broad and potent neutralization of HIV-
1 by a gp41-specific human antibody. Nature 491: 406-+. doi: 10.1038/nature11544 PMID: 23151583
9. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on
gp41 of human immunodeficiency virus type 1. J Virol 67: 6642–6647. PMID: 7692082
10. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, et al. (2004) Structure and mechanistic analysis
of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol
78: 10724–10737. PMID: 15367639
11. Julien JP, Bryson S, Nieva JL, Pai EF (2008) Structural details of HIV-1 recognition by the broadly neu-
tralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-
binding site. J Mol Biol 384: 377–392. doi: 10.1016/j.jmb.2008.09.024 PMID: 18824005
12. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibod-
ies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glyco-
protein gp41. J Virol 75: 10892–10905. PMID: 11602729
13. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, et al. (1994) Cross-neutralizing activity against
divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J
Virol 68: 4031–4034. PMID: 7514684
14. Zhu Z, Qin HR, ChenW, Zhao Q, Shen X, et al. (2011) Cross-reactive HIV-1-neutralizing human mono-
clonal antibodies identified from a patient with 2F5-like antibodies. J Virol 85: 11401–11408. doi: 10.
1128/JVI.05312-11 PMID: 21880764
15. Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, et al. (2014) Structural basis for HIV-1 neutralization by 2F5-
like antibodies m66 and m66.6. J Virol 88: 2426–2441. doi: 10.1128/JVI.02837-13 PMID: 24335316
16. Julien JP, Huarte N, Maeso R, Taneva SG, Cunningham A, et al. (2010) Ablation of the complementar-
ity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutraliz-
ing capacity without affecting core epitope binding. J Virol 84: 4136–4147. doi: 10.1128/JVI.02357-09
PMID: 20147404
17. Chen J, Frey G, Peng H, Rits-Volloch S, Garrity J, et al. (2014) Mechanism of HIV-1 neutralization by
antibodies targeting a membrane-proximal region of gp41. J Virol 88: 1249–1258. doi: 10.1128/JVI.
02664-13 PMID: 24227838
18. Zhu J, Ofek G, Yang Y, Zhang B, Louder MK, et al. (2013) Mining the antibodyome for HIV-1-neutraliz-
ing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc
Natl Acad Sci U S A 110: 6470–6475. doi: 10.1073/pnas.1219320110 PMID: 23536288
Developmental Pathway of Antibody 10E8
PLOSONE | DOI:10.1371/journal.pone.0157409 June 14, 2016 20 / 21
19. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific auto-
reactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906–1908. PMID: 15860590
20. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, et al. (2006) A checkpoint for autoreac-
tivity in human IgM+memory B cell development. J Exp Med 203: 393–400. PMID: 16446381
21. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of
HIV-1 by a gp41-specific human antibody. Nature 491: 406–412. doi: 10.1038/nature11544 PMID:
23151583
22. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural Basis for Broad and Potent Neutrali-
zation of HIV-1 by Antibody VRC01. Science 329: 811–817. doi: 10.1126/science.1192819 PMID:
20616231
23. Majeed S, Ofek G, Belachew A, Huang CC, Zhou T, et al. (2003) Enhancing protein crystallization
through precipitant synergy. Structure 11: 1061–1070. PMID: 12962625
24. Otwinowski Z, Minor Wladek (1997) Processing of X-ray diffraction data collected in oscillation model.
Methods in Enzymology 276: 307–326.
25. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallo-
graphic software. J Appl Crystallogr 40: 658–674. PMID: 19461840
26. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive
Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66:
213–221. doi: 10.1107/S0907444909052925 PMID: 20124702
27. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystal-
logr D Biol Crystallogr 66: 486–501. doi: 10.1107/S0907444910007493 PMID: 20383002
28. Davis IW, Murray LW, Richardson JS, Richardson DC (2004) MOLPROBITY: structure validation and
all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res 32: W615–619.
PMID: 15215462
29. DeLanoWL (2002) The PyMOLMolecular Graphics System. San Carlos, CA: DeLano Scientific.
30. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. (2011) Focused evolution of HIV-1 neutralizing anti-
bodies revealed by structures and deep sequencing. Science 333: 1593–1602. doi: 10.1126/science.
1207532 PMID: 21835983
31. Ye J, Ma N, Madden TL, Ostell JM (2013) IgBLAST: an immunoglobulin variable domain sequence
analysis tool. Nucleic Acids Res 41: W34–40. doi: 10.1093/nar/gkt382 PMID: 23671333
32. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) Clustal W and Clustal X
version 2.0. Bioinformatics 23: 2947–2948. PMID: 17846036
33. Aouinti S, Malouche D, Giudicelli V, Kossida S, Lefranc MP (2015) IMGT/HighV-QUEST Statistical Sig-
nificance of IMGT Clonotype (AA) Diversity per Gene for Standardized Comparisons of Next Genera-
tion Sequencing Immunoprofiles of Immunoglobulins and T Cell Receptors. PLoS One 10: e0142353.
doi: 10.1371/journal.pone.0142353 PMID: 26540440
34. Felsenstein J (1989) PHYLIP—Phylogeny Inference Package (Version 3.2). Cladistics 5: 164–166.
35. Huson DH, Scornavacca C (2012) Dendroscope 3: an interactive tool for rooted phylogenetic trees and
networks. Syst Biol 61: 1061–1067. doi: 10.1093/sysbio/sys062 PMID: 22780991
36. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C (1991) Sequences of Proteins of Immunological
Interest: U.S. Department of Health and Human Service, National Institutes of Health, Bethesda MD.
37. Ofek G, Guenaga FJ, Schief WR, Skinner J, Baker D, et al. (2010) Elicitation of structure-specific anti-
bodies by epitope scaffolds. Proc Natl Acad Sci U S A 107: 17880–17887. doi: 10.1073/pnas.
1004728107 PMID: 20876137
38. Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, et al. (2013) The effects of somatic hypermutation
on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog
9: e1003754. doi: 10.1371/journal.ppat.1003754 PMID: 24278016
39. Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, et al. (2015) Viral variants that
initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med 21:
1332–1336. doi: 10.1038/nm.3963 PMID: 26457756
Developmental Pathway of Antibody 10E8
PLOSONE | DOI:10.1371/journal.pone.0157409 June 14, 2016 21 / 21
